Glycomet Trio Forte 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 1000mg, and Voglibose 0.2mg, formulated for sustained release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, minimizing postprandial hyperglycemia. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, offering comprehensive glycemic management. Glycomet Trio Forte 2 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy. The sustained-release formulation ensures a gradual release of active ingredients, enhancing patient compliance and reducing gastrointestinal side effects commonly associated with Metformin. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. This medication should be used under medical supervision, with caution in patients with renal or hepatic impairment, and is contraindicated in cases of diabetic ketoacidosis or severe infections.